Alopecia areata (AA) is an autoimmune disease characterized by non-scarring alopecia with T-cell infiltration at the affected hair follicle.
Our aim was to study the potential link between hepatitis B virus (HBV) antigen exposure and AA.
Two pediatric patients with AA following hepatitis B vaccination were identified in a general dermatology clinic. A bioinformatics analysis and an electronic medical record (EMR) database query were performed at the University of Rochester Medical Center to identify patients with AA, coexisting viral infections, vaccinations, or interferon (IFN) therapy in order to determine if the presence of AA and these conditions was higher than in AA patients without these associated conditions or therapy.
An increased frequency of AA among those who received the HBV surface protein antigen [odds ratio (OR) 2.7, p < 0.0001] was identified, and an independent analysis revealed an increased frequency of AA in those receiving IFN-β treatment (OR 8.1, p < 0.05). One potential antigenic target identified was SLC45A2, a melanosomal transport protein important in skin and hair pigmentation. The longest potential vaccine peptide fragment match (8-mer) was to a segment of natural killer (NK) cell inhibitory receptors, KIR3DL2 and KIR3DL1. Predictive modeling of major histocompatibility complex (MHC)-peptide binding demonstrated potential binding of this peptide to MHC relevant to AA.
The results will need to be verified in additional patient databases allowing analysis of temporal relationships, and with molecular experiments of the identified antigens.
Our data confirm associations between viral infection and IFN treatment with AA. It establishes that the hepatitis B surface protein antigen has shared epitopes with human killer immunoglobulin-like receptors.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med. 2012;366(16):1515–25.
Paus R, Nickoloff BJ, Ito T. A ‘hairy’ privilege. Trends Immunol. 2005;26(1):32–40.
Becker JC, Varki N, Brocker EB, Reisfeld RA. Lymphocyte-mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. J Invest Dermatol. 1996;107(4):627–32.
Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med. 1993;66(6):541–54.
Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS. Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol. 2001;117(6):1357–62.
Betz RC, Petukhova L, Ripke S, Huang H, Menelaou A, Redler S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.
Dudda-Subramanya R, Alexis AF, Siu K, Sinha AA. Alopecia areata: genetic complexity underlies clinical heterogeneity. Eur J Dermatol. 2007;17(5):367–74.
Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102–11.
Freyschmidt-Paul P, McElwee KJ, Hoffmann R, Sundberg JP, Vitacolonna M, Kissling S, et al. Interferon-gamma-deficient mice are resistant to the development of alopecia areata. Br J Dermatol. 2006;155(3):515–21.
Gilhar A, Kam Y, Assy B, Kalish RS. Alopecia areata induced in C3H/HeJ mice by interferon-gamma: evidence for loss of immune privilege. J Invest Dermatol. 2005;124(1):288–9.
Jabbari A, Nguyen N, Cerise JE, Ulerio G, de Jong A, Clynes R, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–3.
Suarez-Farinas M, Ungar B, Noda S, Shroff A, Mansouri Y, Fuentes-Duculan J, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–87.
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–9.
Agesta N, Zabala R, Diaz-Perez JL. Alopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205(3):300–1.
Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol. 2007;19(9):817–20.
Musch E, Andus T, Malek M. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment Pharmacol Ther. 2002;16(7):1233–9.
Radny P, Bauer J, Caroli UM, Eigentler TK, Kamin A, Metzler G, et al. Alopecia areata induced by adjuvant treatment with alpha-interferon in malignant melanoma? Dermatology. 2004;209(3):249–50.
Ghoreishi M, Martinka M, Dutz JP. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol. 2010;163(1):57–62.
Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–90.
Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370–1.
Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–5.
Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.
Maticic M, Poljak M, Lunder T, Rener-Sitar K, Stojanovic L. Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. J Eur Acad Dermatol Venereol. 2008;22(7):779–88.
Podanyi B, Lengyel G, Harsing J, Becker K, Horvath A. Skin diseases associated with chronic hepatitis C [in Hungarian]. Orvosi Hetilap. 1998;139(44):2633–7.
Rodriguez TA, Duvic M. National Alopecia Areata Registry. Onset of alopecia areata after Epstein-Barr virus infectious mononucleosis. J Am Acad Dermatol. 2008;59(1):137–9.
Skinner RB Jr, Light WH, Bale GF, Rosenberg EW, Leonardi C. Alopecia areata and presence of cytomegalovirus DNA. JAMA. 1995;273(18):1419–20.
Jadali Z, Mansouri P, Jadali F. These is no relationship between hepatitis C virus and alopecia areata. Eur J Dermatol. 2006;16(1):94–5.
Offidani A, Amerio P, Bernardini ML, Feliciani C, Bossi G. Role of cytomegalovirus replication in alopecia areata pathogenesis. J Cutan Med Surg. 2000;4(2):63–5.
Wise RP, Kiminyo KP, Salive ME. Hair loss after routine immunizations. JAMA. 1997;278(14):1176–8.
de Andrade M, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M. Alopecia areata in families: association with the HLA locus. J Investig Dermatol Symp Proc. 1999;4(3):220–3.
Frentz G, Thomsen K, Jakobsen BK, Svejgaard A. HLA-DR4 in alopecia areata. J Am Acad Dermatol. 1986;14(1):129–30.
Haida Y, Ikeda S, Takagi A, Komiyama E, Mabuchi T, Ozawa A, et al. Association analysis of the HLA-C gene in Japanese alopecia areata. Immunogenetics. 2013;65(7):553–7.
Kavak A, Baykal C, Ozarmagan G, Akar U. HLA in alopecia areata. Int J Dermatol. 2000;39(8):589–92.
Kianto U, Reunala T, Karvonen J, Lassus A, Tiilikainen A. HLA-B12 in alopecia areata. Arch Dermatol. 1977;113(12):1716.
Morling N, Frentz G, Fugger L, Georgsen J, Jakobsen B, Odum N, et al. DNA polymorphism of HLA class II genes in alopecia areata. Dis Markers. 1991;9(1):35–42.
Odum N, Morling N, Georgsen J, Jakobsen BK, Frentz G, Jensen GF, et al. HLA-DP antigens in patients with alopecia areata. Tissue Antigens. 1990;35(3):114–7.
Orecchia G, Belvedere MC, Martinetti M, Capelli E, Rabbiosi G. Human leukocyte antigen region involvement in the genetic predisposition to alopecia areata. Dermatologica. 1987;175(1):10–4.
Xiao FL, Zhou FS, Liu JB, Yan KL, Cui Y, Gao M, et al. Association of HLA-DQA1 and DQB1 alleles with alolpecia areata in Chinese Hans. Arch Dermatol Res. 2005;297(5):201–9.
Zhang J, Shao J, Wu X, Mao Q, Wang Y, Gao F, et al. Type I interferon related genes are common genes on the early stage after vaccination by meta-analysis of microarray data. Hum Vaccin Immunother. 2015;11(3):739–45.
Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest. 2004;84(9):1148–59.
Videira IF, Moura DF, Magina S. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013;88(1):76–83.
Graf J, Hodgson R, van Daal A. Single nucleotide polymorphisms in the MATP gene are associated with normal human pigmentation variation. Hum Mutat. 2005;25(3):278–84.
Jiang Y, Wu S, Zhou F, Bice T, Zhang Z, Liu J, et al. Alteration of inhibitory and activating natural killer cell receptor expression on T cells in human immunodeficiency virus-infected Chinese. Microbiol Immunol. 2011;55(10):715–25.
O’Connor GM, McVicar D. The yin-yang of KIR3DL1/S1: molecular mechanisms and cellular function. Crit Rev Immunol. 2013;33(3):203–18.
Bjorkstrom NK, Beziat V, Cichocki F, Liu LL, Levine J, Larsson S, et al. CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells. Blood. 2012;120(17):3455–65.
Wong W, Minchin RF. Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells. Int J Biochem Cell Biol. 1996;28(11):1223–32.
Doganay L, Fejzullahu A, Katrinli S, Yilmaz Enc F, Ozturk O, Colak Y, et al. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B. World J Gastroenterol. 2014;20(25):8179–86.
Al-Qahtani AA, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, et al. Association between HLA variations and chronic hepatitis B virus infection in Saudi Arabian patients. PLoS One. 2014;9(1):e80445.
Wang L, Zou ZQ, Wang K. Clinical relevance of HLA gene variants in HBV Infection. J Immunol Res. 2016;2016:9069375.
This study was supported by the Skin Cancer Research and Education Fund from the Rochester General Foundation.
Conflicts of interest
Christopher T. Richardson, Matthew S. Hayden, Elaine S. Gilmore, and Brian Poligone report no conflicts of interest relevant to this study.
The study was reviewed by the Institutional Review Board and was found to be exempt.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Richardson, C.T., Hayden, M.S., Gilmore, E.S. et al. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. Am J Clin Dermatol 19, 119–126 (2018). https://doi.org/10.1007/s40257-017-0312-y